Clinical Trial Update: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is evaluating a three-drug combination (trametinib, everolimus, and lenvatinib) for recurrent/refractory advanced solid tumors, incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• LENVIMA (lenvatinib)
• MEKINIST (trametinib)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Solid Tumor, Adult, Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING